AXSM
NASD Axsome Therapeutics, Inc.$179.25 ↑ +0.00 (+0.00%) Trading Up from the previous close of $179.25, $3.30 below the day’s high of $182.55
- YTD change
- -1.86%
- vs 20-day SMA
- -11.69%
- vs 200-day SMA
- -10.21%
Price ranges
Price & Performance
+10.75 (+6.38%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 31.1% away from all-time highs of $260.19
- AXSM is down 2% since the beginning of the year
- AXSM is up 49% over the past 12 months
- AXSM is down 15% over the past 1 month
- 7% of all AXSM investors are betting against AXSM
AXSM reads poor: price sits below both the 20- and 200-day averages, the 12-month move is +49.4%.
- Previous minute
- +$0.00
- Last hour
- +$0.40
- Last 5 days
- -8.56%
- vs 8-day SMA
- -6.53%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.